FlowView Diagnostics develops an algorithm that analyses raw data from a cytometry machine to detect Minimal Residual Disease (MRD) in leukemia and inflammatory diseases. More cells are processed and MRD is detected more precisely compared to expert analysis. Because of this FlowView aims to improve diagnostics and patient care, at a lower cost for society.

Founder:
Ton van den Hoven

Focus area:
Digital Health

Complies with the following Sustainable Development Goals:
SDG 3: Good health and well-being

Contact information:
https://www.flowview.eu/contact-flowview/